AddedRisk Factors
On November 6, 2025, the FDA announced that CASGEVY for SCD was awarded a CNPV. As a result, the [sBLA] for CASGEVY for SCD is eligible for the benefits of this program. However, receipt of the CNPV does not guarantee that any [sBLA] will be approved on an expedited basis or at all. The FDA has stated that the review time for an application of a CNPV recipient may be extended, including because the application is incomplete, if the results of pivotal trial(s) are ambiguous, or, if the review is particularly complex. The CNPV program is in pilot stage, so its implementation, operation, and ultimate impact or benefits are subject to uncertainty.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, current or future collaborators or strategic partners could also become our competitors in the future. Our
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
including patent rights and trade secret protection, as well as entering into confidentiality agreements and in-licensing arrangements.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
Going forward, the USPTO could declare new interferences involving the CVC Group related to the same patents and patent applications referenced above, or any of the CVC Group’s existing or new patents and patent applications. Additionally, the USPTO could declare new interferences with us individually related to our existing wholly-owned patent portfolio or new patents and patent applications we file in the future.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedRisk Factors
product and we may never be able to again research, develop or commercialize a marketable product.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
We must rely on Vertex to manufacture and commercialize CASGEVY. For example, the manufacture of cell and genetic therapies requires significant expertise, and even with the relevant experience and expertise, manufacturers of cell and genetic therapy products often encounter difficulties in production, including difficulties with production costs and yields, quality control, and
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to induce or reward improper performance generally is also governed by the national anti-bribery laws of EU Member States, and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
which in each case, would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
and commercialization objectives and seriously harm our ability to successfully implement our business strategy. If we are unable to retain high quality personnel, our ability to pursue our growth strategy will be limited.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
We will face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, any such changes do not guarantee that we will be effective in maintaining the adequacy of our internal controls,
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
The strength of patents in the biotechnology and pharmaceutical field generally, and the gene-editing field in particular, involves complex legal and scientific questions and can be uncertain. Changes in either the patent laws or their interpretation in the United
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RewordedRisk Factors
Positive Results From Early Preclinical Studies Or Preliminary Results Any positive results from Clinical Trials Of Our Product Candidates Are Not Necessarily Predictive Of The Results Of Later Preclinical Or Clinical Studies And Any Future Clinical Trials Of Our Product Candidates. our preclinical studies or preliminary results from our clinical trials of our product candidates may not necessarily be predictive of the results from required later preclinical studies and clinical trials.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our business, financial condition and results of operations could be adversely affected by general conditions in the global economy, disruption of global financial markets and a recession or market correction, including, for example, as a result of the coronavirus pandemic, uncertain trade policy, political unrest, including as a result of geopolitical tension such as a deterioration in the relationship between the United States and China, escalation of tensions between China and Taiwan, the ongoing military conflict between Russia and Ukraine and related sanctions imposed against Russia, or the Israel-Hamas war, and other global macroeconomic factors such as inflation. inflation, interest rate and currency rate fluctuations, tariffs, changes in or disruptions of certain U.S. governmental agencies, such as the FDA, whether due to a potential or actual U.S. federal government shutdown or otherwise, new laws and regulations or amendments to existing laws and regulations in the U.S. and foreign countries.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, (i) corporate and individual shareholders who are resident in Switzerland for tax purposes, (ii) corporate and individual shareholders who are not resident in Switzerland, and who, in each case, hold their shares as part of a trade or business carried on in Switzerland through a permanent establishment with fixed place of business situated in Switzerland for tax purposes and (iii) Swiss resident private individuals who, for income tax purposes, are classified as “professional securities dealers” for reasons of, inter alia, frequent dealing, or leveraged investments, in shares and other securities (collectively, “Domestic Commercial Shareholders”) are in principle eligible for a full refund or credit against income tax of the Swiss withholding tax if they duly report the underlying income in their income statements or income tax return, as the case may be.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Rights Of Our Shareholders May Be Different From The Rights Of Shareholders In Companies Governed By The Laws Of rights of our shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders and directors of companies governed by the laws of U.S. jurisdictions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our vendors may in turn incorporate generative artificial intelligence AI tools into their offerings without disclosing this use to us, offerings, and the providers of these generative artificial intelligence AI tools may not meet existing or rapidly evolving regulatory or industry standards standards, including with respect to privacy privacy, data security and data protection and may inhibit our or our vendors’ ability to maintain an adequate level of service and experience. integrity.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
In general, the FDA requires the successful completion of two pivotal trials to support approval of a BLA, but in certain circumstances, will approve a BLA based on only one pivotal trial; and our ability to submit and obtain approval of a BLA is ultimately an FDA review decision, which will be dependent upon the data available at such time, and the available data may not be sufficiently robust from a safety and/or efficacy perspective to support the submission or approval of a BLA.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, beginning in 2025, we will no longer have the option to defer certain costs on the CASGEVY program under the Amended A&R Vertex JDCA and We expect that our share of expenses for the development and commercialization of CASGEVY to will increase, and has increased, and that such expenses will exceed exceed, and have exceeded, our share of revenue for the foreseeable future.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, beginning in 2025, we will no longer have the option to defer certain costs on the CASGEVY program under the Amended A&R Vertex JDCA JDCA, and, as a result, we have incurred increased development and expect our share of commercialization expenses for the development and commercialization of CASGEVY to increase, and that such expenses will exceed our share of revenue for the foreseeable future. program.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although there have been significant advances in recent years in the fields of gene therapy and genome editing, including CRISPR/Cas9 gene editing technology, such technologies, including in vivo CRISPR-based genome editing technologies in particular, are relatively new and only a limited number of clinical trials of product candidates based on such gene editing technologies have been commenced and their therapeutic utility is largely unproven.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For tax years beginning after December 31, 2017, each Each Ten Percent Shareholder of a CFC is also required to include in income such Ten Percent Shareholder’s share of “global intangible low-taxed income” (for tax years beginning after December 31, 2017 and prior to January 1, 2026) and “net CFC tested income” (for tax years beginning after December 31, 2025) with respect to such CFC.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
If a prolonged government shutdown occurs, occurs or if staffing changes prevent the FDA, the SEC or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, including formal and informal interactions with product developers, it could significantly impact the ability of the FDA and the SEC to timely review and process our submissions, which could have a material adverse effect on our business and our timelines.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Beginning in 2025, we will no longer have the option to defer such costs on the CASGEVY program.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If, for example, other certain banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
In addition, we have a number of earlier stage investigational in vivo programs leveraging gene disruption in the liver for both common and rare diseases, including CTX340, directed towards angiotensinogen for the treatment of refractory hypertension; our next-generation LPA program, CTX321 directed towards LPA, the gene encoding apolipoprotein(a), a major component of lipoprotein(a), or Lp(a), and CTX460, directed towards SERPINA1 using our proprietary SyNTase editing platform, for the treatment of alpha-1 antitrypsin deficiency. CTX340 and CTX321 are currently in IND-enabling studies in patients with refractory hypertension and in patients with elevated Lp(a), which has been shown to have an independent association with major adverse cardiovascular events, respectively. We are progressing CTX460 through preclinical studies. We are also pursuing additional delivery technologies, including LNPs, for delivery to tissues beyond the liver, including hematopoietic stem cells and T cells.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Our siRNA-based portfolio includes clinical-stage programs in cardiovascular and thromboembolic diseases, developed in collaboration with Sirius Therapeutics and certain of its affiliates, or Sirius.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
CTX611 (formerly known as SRSD107) is a novel double-stranded, long-acting siRNA, designed to target the human coagulation factor XI, or FXI, messenger RNA and inhibit FXI protein expression. Through modulation of the intrinsic coagulation pathway, CTX611 is intended to provide anticoagulant and antithrombotic effects. Supported by clinical experience conducted by Sirius in two Phase 1 clinical trials, CTX611 is being developed as a long-acting FXI inhibitor with the potential to support infrequent, including semi-annual, subcutaneous administration.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
CTX611 is in an ongoing Phase 2 clinical trial in patients undergoing total knee arthroplasty.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
In autoimmune disease, it is being investigated in an ongoing clinical trial designed to assess the safety and efficacy of the product candidate in adult patients with systemic lupus erythematosus, or SLE, systemic sclerosis, and inflammatory myositis, and a second clinical trial in immune thrombocytopenia purpura and warm autoimmune hemolytic anemia.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
In oncology, the Phase 1/2 clinical trial in adult patients with relapsed or refractory B-cell malignancies who have received at least two prior lines of therapy is ongoing. Eligible disease subtypes include large B-cell lymphoma, or LBCL, follicular lymphoma grade 1-3a, marginal zone lymphoma, and mantle cell lymphoma. Initial positive clinical data generated through December 2025 support the advancement of zugo-cel into the Phase 2 portion of the ongoing Phase 1/2 trial. We have also established a collaboration and clinical supply agreement with Eli Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, further expanding the program’s development in oncology. Zugo-cel has been granted RMAT designation by the U.S. Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
siRNA. In May 2025, we partnered with Sirius and entered into the Sirius Agreement pursuant to which, among other things, we and Sirius will collaborate on the research, development, manufacture, commercialization and use of the Sirius Collaboration Products, including co-development and co-commercialization of CTX611; and (2) Sirius granted us options to exclusively license Sirius siRNA technology to target up to two licensed targets from a list of seven reserved targets for the research, develop, manufacture and commercialization of siRNA Licensed Products, For the first Sirius Collaboration Product successfully developed, we will be the lead party responsible for commercialization efforts in the United States and Sirius will be the lead party responsible for commercialization efforts in Greater China.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Asset acquisition costs related to acquired technology are expensed as acquired in-process research and development at the point that they have no established alternative future use. We classify asset acquisitions of acquired in-process research and development as investing activities on our consolidated statements of cash flows.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Collaboration expense, net, consists of operating expenses under our collaboration with Vertex for the hemoglobinopathies program.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Other income, net consists primarily of interest income earned on investments, as well as the change in fair value of corporate equity securities.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Collaboration expense, net, was $213.5 million for the year ended December 31, 2025, compared to $120.7 million for the year ended December 31, 2024. In 2024, we exercised our option to defer specified costs under the CASGEVY program in excess of the $110.3 million deferral limit under the A&R Vertex JDCA, as amended. The increase of approximately $92.8 million in collaboration expense, net, was primarily attributable to reaching the deferral limit in 2024, as no such limit was applicable in 2025. Absent the deferral limit, the increase was primarily attributable to an increase in our share of CASGEVY operating expenses related to increased commercial and manufacturing costs for CASGEVY when compared to the prior period, which was partially offset by an increase in our share of CASGEVY revenue.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
As described in Note 8 of the notes to the consolidated financial statements included in this Annual Report on Form 10-K, we and Sirius entered into a share issuance agreement and we registered and issued 1,842,105 common shares to Sirius, nominal value CHF 0.03 per share, at an issue price of $38.00 per share as partial consideration for entering into the Sirius Agreement.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedMD&A
In 2023, CASGEVY became the first-ever approved CRISPR-based gene-editing therapy in the world. To date, CASGEVY has been approved in the United States, European Union, Great Britain, Canada, Switzerland, Kingdom of Saudi Arabia, Kingdom of
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
CTX112 is being developed for both hematologic malignancies and autoimmune indications. It is being investigated in an ongoing clinical trial designed to assess the safety and efficacy of the product candidate in adult patients with relapsed or refractory B-cell malignancies who have received at least two prior lines of therapy, as well as an ongoing clinical trial in adult patients with systemic lupus erythematosus, systemic sclerosis, and inflammatory myositis. Early clinical studies conducted by third parties have shown that CD19-directed autologous CAR T therapy can produce long-lasting remissions in multiple autoimmune indications by deeply depleting B cells. Our first generation allogeneic CD19-directed CAR T program has demonstrated effective depletion of B cells in oncology settings, which supports the potential for CTX112 in autoimmune diseases.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
CTX131 is being developed for both solid tumors and hematologic malignancies. It is being investigated in ongoing clinical trials designed to assess the safety and efficacy of the candidate in adult patients with relapsed or refractory solid tumors, as well as in hematologic malignancies, including, including T cell lymphomas, or TCL. We believe allogeneic CAR T approaches for TCL may have greater potential to meet the unmet need in this patient population given the patients’ own T cells are not suitable for autologous manufacturing.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
CTX320 is being investigated in an ongoing clinical trial targeting LPA, the gene encoding apo(a), a critical component of Lp(a) in patients with elevated Lp(a), which has shown to have an independent association with major adverse cardiovascular events.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
Building upon CTX310 and CTX320, we are progressing CTX340, targeting angiotensinogen for refractory hypertension, as well as CTX450, targeting 5’-aminolevulinate synthase 1 for acute hepatic porphyria, through preclinical studies. In addition, we have programs focused on gene correction in the liver, including programs leveraging technologies developed by our CRISPR-X research team. Finally, we are pursuing additional delivery technologies, including LNPs, for delivery to tissues beyond the liver, including hematopoietic stem cells.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
Diabetes. Beginning in 2018, we partnered with ViaCyte, Inc., or ViaCyte (now a wholly-owned subsidiary of Vertex), to pursue the discovery, development and commercialization of gene-edited allogeneic stem cell therapies for the treatment of diabetes. In 2023, ViaCyte elected to opt-out of the collaboration with us for the co-development and co-commercialization of gene-edited stem cell therapies for the treatment of diabetes. Per the opt-out terms, the on-going collaboration assets will be wholly owned by us, subject to a royalty on future sales owed to ViaCyte. Our product candidate, CTX211, being developed for the potential treatment of T1D, resulted from this collaboration, and which we are continuing to advance in a Phase 1 clinical trial. Additionally, in 2023, we entered into a non-exclusive license agreement with Vertex for Vertex to utilize certain of our gene-editing intellectual property to exploit certain products for the diagnosis, treatment or prevention of diabetes type 1, diabetes type 2 or insulin dependent/requiring diabetes throughout the world. To date, we have recognized revenue of $205 million in upfront and milestone payments and remain eligible to receive additional research and development milestones and royalties on future products under the license.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
In 2022, the sale of common shares pursuant to the 2019 Sales Agreement and the applicable prospectus supplement was not significant.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
Years Ended December 31, 2024 2023 (in thousands) Net cash used in operating activities $ (142,774) $ (260,375) Net cash (used in) provided by investing activities (280,481) 374,647 Net cash provided by financing activities 331,984 62,664 Effect of exchange rate changes on cash (21) 73 (Decrease) increase in cash and restricted cash $ (91,292) $ 177,009
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RewordedMD&A
In August 2019, we We entered into an Open Market Sale AgreementSM AgreementSM, or the Sales Agreement, with Jefferies LLC under which we were we, at our sole discretion, are able to offer and sell, from time to time at our sole discretion through Jefferies, as our sales agent, prevailing market prices, our common shares, par value of CHF 0.03 per share, or the August 2019 Sales Agreement. shares.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024, In 2025, we have common shares having aggregate gross proceeds up to $363.7 million remaining under our current prospectus supplement, and we have issued and sold an aggregate of 1.9 6.1 million common shares under the 2021 ATM at an average price of $122.73 $59.63 per share for aggregate proceeds of $233.2 $359.0 million, which were net of equity issuance costs of $3.1 $4.7 million, excluding stamp taxes. taxes of $3.6 million.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024, In 2025, we have common shares having aggregate gross proceeds up to $363.7 million remaining under our current prospectus supplement, and we have issued and sold an aggregate of 1.9 0.7 million common shares under the 2025 ATM at an average price of $122.73 $60.81 per share for aggregate proceeds of $233.2 $42.3 million, which were net of equity issuance costs of $3.1 $0.5 million, excluding stamp taxes. taxes of $0.4 million.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Under the A&R Vertex JDCA, as amended, we are allowed for 2022, 2023 and 2024, the Company had an option to defer a portion of our its share of costs under the arrangement if spending on the CASGEVY program exceeds exceeded specified amounts. amounts, which the Company exercised in each such year, resulting in deferred costs of $221.8 million, in the aggregate.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024, 2025, we have common shares having aggregate gross proceeds up to $363.7 million remaining under our current prospectus supplement, and we have issued and sold an aggregate of 1.9 8.0 million common shares under the 2021 ATM at an average price of $122.73 $74.77 per share for aggregate proceeds of $233.2 $592.2 million, which were net of equity issuance costs of $3.1 $7.8 million, excluding stamp taxes. taxes of $5.9 million.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities for the year ended December 31, 2023 was $62.7 million and 2025 consisted primarily of net proceeds of $32.7 approximately $397.3 million from the issuance sale of common shares issued in connection with our 2021 ATM and 2025 ATM, in the aggregate, as well as net proceeds of approximately $29.9 $27.7 million from stock option exercises. exercise proceeds.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Our first We have established a leading platform for in vivo programs gene editing and are rapidly advancing a pipeline of in vivo gene editing candidates that target the liver, taking advantage of validated LNP lipid nanoparticle, or LNP, delivery technologies, and aim to treat diseases where we can produce a strong therapeutic effect by safely disrupting a gene with well-understood genetic association.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
While we have made significant progress with our current portfolio of programs, we recognize that we need may be able to continue bring transformative therapies to even more patients by continuing to innovate to unlock the full power potential of gene editing and bring potentially transformative therapies to even more patients. editing.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
CTX310 Our in vivo portfolio includes cardiovascular programs, such as CTX310, directed towards angiopoietin-related protein 3 or ANGPTL3, which is being investigated currently in an ongoing Phase 1b clinical trial targeting ANGPTL3 in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias, or severe hypertriglyceridemia.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
(2) CTX213, a research stage deviceless beta cell replacement product candidate consisting of unencapsulated precursor islet cells derived from edited stem cells; and (3) In addition, we have granted a non-exclusive license to certain of our CRISPR/Cas9 intellectual property to Vertex to accelerate Vertex’s development of hypoimmune cell therapies for T1D in exchange for certain milestones and royalties.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Bahrain and To date, CASGEVY has been approved in the United Arab Emirates States, European Union, Great Britain, Canada, Switzerland and certain countries in the Middle East for the treatment of eligible patients 12 years and older with SCD or TDT.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
General and administrative expenses were $73.5 million for the year ended December 31, 2025, compared to $73.0 million for the year ended December 31, 2024, compared to $76.2 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new